When the Danish drugmaker Novo Nordisk wanted to test whether the main ingredient in Ozempic, its wildly popular weight-loss and diabetes drug, could also treat liver disease,

📰

Continue Reading on New York Times

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →